Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-
Promising CAR T-Cell Therapy Targets Cutaneous, Rare Melanomas miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-
A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to the widely used immunotherapy drugs known as PD-1 inhibitors.